Sisman, P. Et Al. 2020. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients. CLINICAL LABORATORY , vol.66, no.1-2 , 9-16.

Sisman, P., ÖZ GÜL, Ö., Dirican, M., Bal, A. S., CANDER, S., & ERTÜRK, E., (2020). Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients. CLINICAL LABORATORY , vol.66, no.1-2, 9-16.

Sisman, Pinar Et Al. "Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients," CLINICAL LABORATORY , vol.66, no.1-2, 9-16, 2020

Sisman, Pinar Et Al. "Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients." CLINICAL LABORATORY , vol.66, no.1-2, pp.9-16, 2020

Sisman, P. Et Al. (2020) . "Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients." CLINICAL LABORATORY , vol.66, no.1-2, pp.9-16.

@article{article, author={Pinar Sisman Et Al. }, title={Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients}, journal={CLINICAL LABORATORY}, year=2020, pages={9-16} }